Liquidia (NASDAQ:LQDA) Director Arthur Kirsch Sells 15,000 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Arthur Kirsch sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $60.22, for a total value of $903,300.00. Following the completion of the sale, the director directly owned 15,000 shares in the company, valued at $903,300. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Liquidia Stock Up 0.8%

NASDAQ LQDA opened at $55.53 on Thursday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The stock has a market capitalization of $4.94 billion, a PE ratio of 396.66 and a beta of 0.58. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $63.46. The business’s 50-day moving average is $45.73 and its 200 day moving average is $39.16.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.Liquidia’s quarterly revenue was up 4187.1% on a year-over-year basis. Sell-side analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on LQDA shares. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research report on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Finally, Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $50.88.

Institutional Trading of Liquidia

A number of hedge funds have recently made changes to their positions in the stock. Caprock Group LLC bought a new position in Liquidia in the 3rd quarter valued at approximately $37,114,000. Apis Capital Advisors LLC bought a new position in Liquidia in the 3rd quarter valued at approximately $9,569,000. Farallon Capital Management LLC lifted its position in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares in the last quarter. GSA Capital Partners LLP lifted its position in Liquidia by 63.6% in the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after acquiring an additional 24,555 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in Liquidia in the 3rd quarter valued at approximately $1,536,000. 64.54% of the stock is owned by institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).